---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-054600"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2022-02-25T23:59:59+00:00"
generated_at: "2026-06-27T04:16:20.299722+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics director Brett Kaplan resigns from Board effective Feb 25, 2022

## Summary
- Brett Kaplan, M.D. resigned from the Board and all committees, effective February 25, 2022.
- Resignation was not due to any disagreement with the Company's operations, policies, or practices.
- No replacement announced; Board composition changes.

## SEC filing metadata
- accession: 0001193125-22-054600
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2022-02-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000119312522054600/0001193125-22-054600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000119312522054600/d289527d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-054600
- JSON: https://secwatch.observer/filing/0001193125-22-054600.json
- Plain text: https://secwatch.observer/filing/0001193125-22-054600.txt

## Key facts
- Executive change
  Brett Kaplan resigned as director at Compass Therapeutics, Inc..
  - Action: resigned
  - Role: director
  source text: On February 22, 2022, Brett Kaplan, M.D., a member of the Board of Directors (the “Board”) of Compass Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board and all committees thereof, effective February 25, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1738021/000119312522054600/0001193125-22-054600-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.